Summary bridging and addendum reports confirmed dead in ICH benefit-risk reporting guideline
This article was originally published in SRA
Executive Summary
Summary bridging and addendum reports are categorically not needed under the new international guideline on periodic reporting of a drug's benefit-risk profile - E2C(R2) - according to a senior participant in the guideline development process.